• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by PharmaCyte Biotech Inc.

    3/10/25 4:18:48 PM ET
    $PMCB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PMCB alert in real time by email
    DEFA14A 1 pmcb_defa14a.htm FORM DEFA 14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

    (Amendment No. )

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

    ☐     Preliminary Proxy Statement

    ☐     Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐     Definitive Proxy Statement

    ☒     Definitive Additional Materials

    ☐     Soliciting Material Under § 240.14a–12

     

    PharmaCyte Biotech, Inc.

     

    (Name of Registrant as Specified In Its Charter)

     

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

    ☒     No fee required

    ☐     Fee paid previously with preliminary materials

    ☐     Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

     

     

     

     

       

     

     

     

     

     

       

     

     

     

     

       

     

    Get the next $PMCB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PMCB

    DatePrice TargetRatingAnalyst
    11/8/2021Neutral
    HC Wainwright & Co.
    More analyst ratings

    $PMCB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

      Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder value PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD") a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions. MyMD has announced positive data for a 40-patient Phase 2 clinical trial for its lead product, MYMD-1 in sarcopenia, and is moving its clinical program forward in consultation with the U.S. Food and Drug Administration (FD

      5/21/24 9:00:00 AM ET
      $MYMD
      $PMCB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • MyMD Pharmaceuticals Secures Strategic Investments

      Up to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14 Million Up Front MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory conditions, today announced that it has secured $7 million in commitments in two private placement funding rounds led by a strategic investor, PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a clinical-stage biotechnology company developing cellular therapies for cancer and diabetes. An additional $7 million was raised from existing MyMD

      5/21/24 9:00:00 AM ET
      $MYMD
      $PMCB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.

      New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (NASDAQ:FEMY) ("Femasys"), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions, including a lead late-stage product candidate and innovative therapeutic and diagnostic products. This is the Company's first investment in externally developed technology, which it believes will provide significant additional shareholder value and serv

      11/15/23 8:30:00 AM ET
      $FEMY
      $PMCB
      Medical/Dental Instruments
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $PMCB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on PharmaCyte Biotech

      HC Wainwright & Co. initiated coverage of PharmaCyte Biotech with a rating of Neutral

      11/8/21 6:05:27 AM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PMCB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by PharmaCyte Biotech Inc.

      SC 13G/A - PharmaCyte Biotech, Inc. (0001157075) (Subject)

      11/13/24 11:19:35 AM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by PharmaCyte Biotech Inc.

      SC 13G - PharmaCyte Biotech, Inc. (0001157075) (Subject)

      2/14/24 3:38:38 PM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by PharmaCyte Biotech Inc. (Amendment)

      SC 13G/A - PharmaCyte Biotech, Inc. (0001157075) (Subject)

      2/6/24 9:56:28 AM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PMCB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Weinstein Robert

      4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)

      7/17/24 4:59:12 PM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Walker Wayne Remell

      4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)

      7/17/24 4:58:59 PM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Schechter Jonathan

      4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)

      7/17/24 4:58:49 PM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PMCB
    Financials

    Live finance-specific insights

    See more
    • PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.

      New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (NASDAQ:FEMY) ("Femasys"), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions, including a lead late-stage product candidate and innovative therapeutic and diagnostic products. This is the Company's first investment in externally developed technology, which it believes will provide significant additional shareholder value and serv

      11/15/23 8:30:00 AM ET
      $FEMY
      $PMCB
      Medical/Dental Instruments
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

      Expresses Disappointment in the Board's Failure to Articulate a Plan to Maximize Shareholder Value Amid Prolonged Product Development Efforts Despite the Company's Strong Cash Position Criticizes the Company's Dismal Efforts to Communicate with Shareholders Including its Failure to Hold Quarterly Conference Calls Questions the Board and Management's Alignment with Shareholders Given Minimal Stock Ownership and Failure to Purchase Shares in the Open Market Calls on the Company to Actively Enlist Shareholder Participation in a Process to Refresh a Majority of the Directors on the Board with Highly Qualified Candidates to Fill Gaps in the Existing Leadership's Skillset and Bring Fresh Perspecti

      5/11/22 9:00:00 AM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PMCB
    SEC Filings

    See more
    • PharmaCyte Biotech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - PharmaCyte Biotech, Inc. (0001157075) (Filer)

      4/24/25 4:47:19 PM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by PharmaCyte Biotech Inc.

      10-Q - PharmaCyte Biotech, Inc. (0001157075) (Filer)

      3/17/25 5:22:56 PM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by PharmaCyte Biotech Inc.

      DEFA14A - PharmaCyte Biotech, Inc. (0001157075) (Filer)

      3/10/25 4:18:48 PM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PMCB
    Leadership Updates

    Live Leadership Updates

    See more
    • Oblong Appoints Two New Directors to its Board

      Jonathan Schechter and Robert Weinstein Join Oblong's Board of Directors Oblong, Inc. (NASDAQ:OBLG) ("Oblong" or the "Company"), the award-winning maker of multi-stream collaboration solutions, today appointed two new directors to its board. Jonathan Schechter, Partner, The Special Equities Group, and Robert Weinstein, Chief Financial Officer, Synaptogenix, Inc. have joined Oblong's board of directors. In addition, Jim Lusk and Matthew Blumberg have retired from the Oblong board. "We're delighted to welcome Jonathan and Robert to the Oblong board of directors," said Pete Holst, President and CEO. "Both individuals bring a wealth of knowledge in mergers and acquisitions, digital transfor

      5/30/23 8:00:00 AM ET
      $OBLG
      $PMCB
      $PTPI
      $SNPX
      Computer Software: Programming Data Processing
      Technology
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

      Company Appoints Five New Independent Directors to Reconstituted Board PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that PharmaCyte and Iroquois Master Fund Ltd. and its affiliates, the beneficial owners of approximately 6.7% of PharmaCyte's outstanding shares of common stock, have signed a Cooperation Agreement that includes naming two of Iroquois' director designees to PharmaCyte's reconstituted Board of Directors. Pursuant to the Agreement, Iroquois' director designees, Jonathan L. Schechter and Jo

      8/15/22 8:30:00 AM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

      PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced its preliminary unaudited financial results for fiscal year ended April 30, 2022. Cash Position PharmaCyte had $85.4 million in cash and cash equivalents as of April 30, 2022. Preliminary (Unaudited) 2022 Fiscal Year End Financial Results PharmaCyte expects to report operating expenses of approximately $4.4 million, compared to $3.6 million in the prior fiscal year. This increase is primarily due to expenses associated with PharmaCyte listing on Nasdaq an

      7/11/22 8:30:00 AM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care